6 Analysts Have This to Say About Coherus BioSciences
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 6 analysts have published their opinion on Coherus BioSciences (NASDAQ:CHRS) stock, with 4 bullish and 2 somewhat bullish ratings. The company has an average 12-month price target of $17.67, down 15.86% from the previous average of $21.00.
May 23, 2023 | 2:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus BioSciences has received 6 analyst ratings in the past 3 months, with 4 bullish and 2 somewhat bullish ratings. The average 12-month price target is $17.67, down 15.86% from the previous average.
The majority of analysts have a bullish or somewhat bullish outlook on Coherus BioSciences, which indicates a positive sentiment towards the stock. However, the decrease in the average 12-month price target suggests that the stock's growth potential may be lower than previously anticipated. This could still have a positive impact on the stock price in the short term, as the overall sentiment remains positive.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100